Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 9Lung Neoplasms 9Oropharyngeal Neoplasms 7Mouth Neoplasms 6Laryngeal Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Stomach Neoplasms 4Hypopharyngeal Neoplasms 4Breast Neoplasms 4Adenocarcinoma of Lung 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Paranasal Sinus Neoplasms 2Ovarian Neoplasms 2Medulloblastoma 2Lymphoid Interstitial Pneumonia 2Liver Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Anus Neoplasms 2Urethral Neoplasms 1

Interventions

pembrolizumab 2Radiotherapy 2Etoposide 2Carboplatin 2sintilimab 1irinotecan sucrosofate 1durvalumab 1camrelizumab 1atezolizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Epirubicin 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Small Cell Lung Cancer Extensive Stage × Platinum × Clear all
NCT05745350 2025-02-11

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡